Lantern Pharma(LTRN) - 2023 Q2 - Earnings Call Presentation

Second Quarter 2023 Operating & Financial Results Conference Call / Webinar NASDAQ: LTRN 1 Nasdaq: LTRN RADR® can predict and stratify real-world patients for clinical trials with 88% Accuracy LANTERN'S DRUG DEVELOPMENT MODEL AND OBJECTIVES Accelerated timelines; reduced costs and risks Lantern's diverse & unique AI-driven pipeline of 14 drug programs includes the Phase 2 Harmonic™ trial and RADR® collaborations August 9th, 2023 4:30 PM Eastern Time Forward Looking Statements > Lantern P h a r m a Lantern i ...